We See Things
We See (The Right) Things
Novel Assets
Novel Assets
We source novel assets from a worldwide network.
Winning Investments
Winning Investments
Our leadership has decades of experience selecting winners.
Mitigate Risk
Mitigate Risk
We mitigate time, cost, and risk for FDA approval.
DEAL CHARACTERISTICS
Medical Devices
- Novel Impact
- Diagnostic and Tools
- Class 2 Devices
Therapeutics
- Oncology
- Infectious Disease
- Metabolic
- Personal Health
Get a deeper understanding of what we do
Leadership
Our Team
We back biotech and medtech founders with the expertise and experience needed to accelerate innovation and growth. Our partners have led successful drug and device approvals, launched and scaled life sciences ventures, and built global investment platforms.
Collectively, our team brings decades of experience in regulatory strategy, product development, venture investing, and company building. From securing over 85 NDA/BLA approvals to pioneering mRNA delivery systems and remote patient monitoring, we understand what it takes to move technologies from concept to clinic—and beyond.
Our backgrounds span clinical science, venture capital, medical communications, and operational leadership. We support our portfolio companies not just with capital, but with a hands-on approach that includes guidance on fundraising, FDA strategy, team development, and commercialization.
Jim Sergi, MSN
Partner
John Stanton
Partner
Richard Moran, Ph.D.
Partner
Built on the expertise of QNova LifeSciences
Results
Drugs, Diagnostics & Devices
Company Valuations on Average
Successful U.S. FDA IND, NDA, BLA, 505(b)1 and 505(b)2 submissions
Drugs Developed by the QNova LifeSciences Team
%
FDA Medical Device Approval Rate (Class I, II, III)
%
FDA IND Approvals with no Clinical Holds
%
Reduction in Development
%
Reduction in Regulatory Cost
Reach out to our team to discuss how you can join us.